|
[1]
|
Fife, B.T. and Pauken, K.E. (2011) The Role of the PD-1 Pathway in Autoimmunity and Peripheral Tolerance. Annals of the New York Academy of Sciences, 1, 677-704. http://dx.doi.org/10.1111/j.1749-6632.2010.05919.x [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Riella, L.V., Paterson, A.M., Sharpe, A.H., et al. (2012) Role of the PD-1 Pathway in the Immune Response. American Journal of Transplantation, 12, 2575-2587. http://dx.doi.org/10.1111/j.1600-6143.2012.04224.x [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Dai, S., Jia, R., Zhang, X., et al. (2014) The PD-1/PD-Ls Pathway and Autoimmune Diseases. Cellular Immunology, 290, 72-79. http://dx.doi.org/10.1016/j.cellimm.2014.05.006 [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., et al. (2014) Programmed Death-1 Pathway in Cancer and Autoimmunity. Clinical Immunology, 153, 145-152. http://dx.doi.org/10.1016/j.clim.2014.04.010 [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Zheng, P. and Zhou, Z. (2015) Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer, 20, 15-18. http://dx.doi.org/10.4137/BIC.S29325 [Google Scholar] [CrossRef]
|
|
[6]
|
Schmid-Bindert, G. and Jiang, T. (2015) First-Line Nivolumab (anti-PD-1)Monotherapy in Advanced NSCLC: The Story of Immune Checkpoint Inhibitors and “the Sorcerers Apprentice”. Translational Lung Cancer Research, 4, 215-216. http://dx.doi.org/10.3978/j.issn.2218-6751.2015.01.12 [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Zhou, J., Cheung, A.K., Liu, H., et al. (2013) Potentiating Functional Antigen-Specific CD8(+)T Cell Immunity by a Novel PD1 Isoform-Based Fusion DNA Vaccine. Molecular Therapy, 21, 1445-1455.
http://dx.doi.org/10.1038/mt.2013.63 [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Patsoukis, N., Brown, J., Petkova, V., et al. (2012) Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Science Signaling, 5, ra46.
http://dx.doi.org/10.1126/scisignal.2002796 [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Karyampudi L., Lamichhane, P., Krempski, J., et al. (2016) PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Research, 76, 239-250.
http://dx.doi.org/10.1158/0008-5472.CAN-15-0748 [Google Scholar] [CrossRef]
|
|
[10]
|
Nishimura, H., Nose, M., Hiai, H., et al. (1999) Development of Lu-pus-Like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity, 11, 141-151.
http://dx.doi.org/10.1016/S1074-7613(00)80089-8 [Google Scholar] [CrossRef]
|
|
[11]
|
Zamani, M.R., Asbagh, F.A., Massoud, A.H., et al. (2015) Association between a PD-1 Gene Polymorphism and Antisperm Antibody-Related Infertility in Iranian Men. Journal of Assisted Reproduction and Genetics, 32, 103-106.
http://dx.doi.org/10.1007/s10815-014-0371-4 [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Fankhauser, C.D., Curioni-Fontecedro, A., Allmann, V., et al. (2015) Frequent PD-L1 Expression in Testicular Germ Cell Tumors. British Journal of Cancer, 113, 411-413. http://dx.doi.org/10.1038/bjc.2015.244 [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Ascierto, P.A. and Marincola, F.M. (2015) 2015: The Year of Anti-PD-1/PD-L1s against Melanoma and Beyond. EBioMedicine, 2, 92-93. http://dx.doi.org/10.1016/j.ebiom.2015.01.011 [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Velu, V., Shetty, R.D., Larsson, M., et al. (2015) Role of PD-1 Co-Inhibitory Pathway in HIV Infection and Potential Therapeutic Options. Retrovirology, 12, 182-190. http://dx.doi.org/10.1186/s12977-015-0144-x [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Owusu Sekyere, S., Suneetha, P.V., Kraft, A.R., et al. (2015) A Heterogeneous Hierarchy of Co-Regulatory Receptors Regulates Exhaustion of HCV-Specific CD8 T Cells in Patients with Chronic Hepatitis C. Journal of Hepatology, 62, 31-40. http://dx.doi.org/10.1016/j.jhep.2014.08.008 [Google Scholar] [CrossRef] [PubMed]
|